SCHEMBL24349249

SCHEMBL24349249

Cc1nc(COC(=O)N2CCC(O)C2)sc1-c1csc(-c2cc(F)c(O)c(F)c2F)n1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 5/20 0.58
▸ PIK3CA P42336 3/20 0.36
▸ PIK3CD O00329 2/20 0.36
▸ ENPP2 Q13822 5/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PIK3CB P42338 2/20 0.32
▸ USP30 Q70CQ3 1/20 0.31
▸ TRPV4 Q9HBA0 2/20 0.31
▸ PIK3CG P48736 2/20 0.31
▸ PI4KB Q9UBF8 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24348999 0.89 BPGM (0.57) BPGMPIK3CAPIK3CDENPP2PIK3CB
SCHEMBL24348395 0.88 BPGM (0.47) BPGMENPP2HTR2C
SCHEMBL24348024 0.86 BPGM (0.45) BPGMPIK3CAPIK3CDENPP2TRPV4
SCHEMBL24348492 0.86 BPGM (0.53) BPGMPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL24348498 0.80 BPGM (0.57) BPGMPIK3CAPIK3CDPIK3CBTRPV4
SCHEMBL24348057 0.80 BPGM (0.69) BPGMPIK3CAPIK3CDLMNAMAPT
SCHEMBL24348461 0.80 BPGM (0.46) BPGMENPP2
SCHEMBL24348968 0.79 BPGM (0.62) BPGMPIK3CAPIK3CDMAPTPIK3CB
SCHEMBL24348485 0.77 BPGM (0.69) BPGMPIK3CAPIK3CDLMNAMAPT
SCHEMBL24348039 0.75 BPGM (0.71) BPGMPIK3CAPIK3CDLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885PIK3CA 568/4885PIK3CD 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback